First in a human: gene therapy fixed a one-letter DNA typo inside one patient's liver to treat alpha-1 antitrypsin deficiency, an inherited disease that damages the liver and lungs. The patient now makes the working protein, and no unwanted edits were found. New hope for avoiding a liver transplant.
In a landmark achievement in the field of genetic medicine, researchers have reported the very first published case in a peer-reviewed journal of a successful clinical treatment of a patient with alpha-1 antitrypsin deficiency (PiZZ) using in vivo gene therapy.